Literature DB >> 9657975

Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.

C Pascaud1, M Garrigos, S Orlowski.   

Abstract

P-Glycoprotein, the plasma membrane protein responsible for the multidrug resistance of some tumour cells, is an active transporter of a number of structurally unrelated hydrophobic drugs. We have characterized the modulation of its ATPase activity by a multidrug-resistance-related cytotoxic drug, vinblastine, and different multidrug-resistance-reversing agents, verapamil and the dihydropyridines nicardipine, nimodipine, nitrendipine, nifedipine and azidopine. P-Glycoprotein ATPase activity was measured by using native membrane vesicles containing large amounts of P-glycoprotein, prepared from the highly multidrug-resistant lung fibroblasts DC-3F/ADX. P-Glycoprotein ATPase is activated by verapamil and by nicardipine but not by vinblastine. Among the five dihydropyridines tested, the higher the hydrophobicity, the higher was the activation factor with respect to the basal activity and the lower was the half-maximal activating concentration. The vinblastine-specific binding on P-glycoprotein is reported by the inhibitions of the verapamil- and the nicardipine-stimulated ATPase. These inhibitions are purely competitive, which means that the bindings of vinblastine and verapamil, or vinblastine and nicardipine, on P-glycoprotein are mutually exclusive. In contrast, verapamil and nicardipine display mutually non-competitive interactions. This demonstrates the existence of two distinct specific sites for these two P-glycoprotein modulators on which they can bind simultaneously and separately to the vinblastine site. The nicardipine-stimulated ATPase activity in the presence of the other dihydropyridines shows mixed-type inhibitions. These dihydropyridines have thus different binding sites that interact mutually to decrease their respective, separately determined affinities. This could be due to steric constraints between sites close to each other. This is supported by the observation that vinblastine binding is not mutually exclusive with nifedipine or nitrendipine binding, whereas it is mutually exclusive with nicardipine. Moreover, verapamil binding also interacts with the five dihydropyridines by mixed inhibitions, with different destabilization factors. On the whole our enzymic data show that P-glycoprotein has distinct but interacting binding sites for various modulators of its ATPase function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657975      PMCID: PMC1219592          DOI: 10.1042/bj3330351

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  42 in total

1.  Interaction of cytostatics and chemosensitizers with the dexniguldipine binding site on P-glycoprotein.

Authors:  R Boer; W R Ulrich; S Haas; C Borchers; V Gekeler; H Boss; M Przybylski; A Schödl
Journal:  Eur J Pharmacol       Date:  1996-01-11       Impact factor: 4.432

2.  Drug-stimulated ATPase activity of a deletion mutant of the human multidrug-resistance protein (MDR1).

Authors:  E Welker; K Szabó; Z Holló; M Müller; B Sarkadi; A Váradi
Journal:  Biochem Biophys Res Commun       Date:  1995-11-13       Impact factor: 3.575

3.  Characterization of the ATPase activity of P-glycoprotein from multidrug-resistant Chinese hamster ovary cells.

Authors:  F J Sharom; X Yu; J W Chu; C A Doige
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

4.  Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates.

Authors:  W D Stein; C Cardarelli; I Pastan; M M Gottesman
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

5.  Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity.

Authors:  M J Borgnia; G D Eytan; Y G Assaraf
Journal:  J Biol Chem       Date:  1996-02-09       Impact factor: 5.157

6.  Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells.

Authors:  U S Rao
Journal:  J Biol Chem       Date:  1995-03-24       Impact factor: 5.157

7.  Effects of lipids on ATPase activity of purified Chinese hamster P-glycoprotein.

Authors:  I L Urbatsch; A E Senior
Journal:  Arch Biochem Biophys       Date:  1995-01-10       Impact factor: 4.013

8.  Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein.

Authors:  U S Rao; G A Scarborough
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

9.  Reversible labeling of a chemosensitizer binding domain of p-glycoprotein with a novel 1,4-dihydropyridine drug transport inhibitor.

Authors:  R Boer; M Dichtl; C Borchers; W R Ulrich; J F Marecek; G D Prestwich; H Glossmann; J Striessnig
Journal:  Biochemistry       Date:  1996-02-06       Impact factor: 3.162

10.  Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein.

Authors:  S Ayesh; Y M Shao; W D Stein
Journal:  Biochim Biophys Acta       Date:  1996-05-24
View more
  33 in total

Review 1.  Molecular properties of bacterial multidrug transporters.

Authors:  M Putman; H W van Veen; W N Konings
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

2.  Inhibition of P-glycoprotein transport function by grapefruit juice psoralen.

Authors:  E J Wang; C N Casciano; R P Clement; W W Johnson
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

3.  Reversal of drug resistance in sarcoma-45 by the new calmodulin antagonist--trihydrochloride of [1,2,5-trimethyl-4-phenyl-4-beta-[N-(beta-ethylamino)-N-4'-methoxybe nzy l]-ethylamino] piperidine (AR-2).

Authors:  A R Alexanian; N S Arutyunian
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4.  Recognition of sulfonylurea receptor (ABCC8/9) ligands by the multidrug resistance transporter P-glycoprotein (ABCB1): functional similarities based on common structural features between two multispecific ABC proteins.

Authors:  Anis Bessadok; Elisabeth Garcia; Hélène Jacquet; Solenne Martin; Alexia Garrigues; Nicolas Loiseau; François André; Stéphane Orlowski; Michel Vivaudou
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

5.  Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket.

Authors:  Tip W Loo; M Claire Bartlett; David M Clarke
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

Review 6.  Role of P-glycoprotein in pharmacokinetics: clinical implications.

Authors:  Jiunn H Lin; Masayo Yamazaki
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Anthrapyridones, a novel group of antitumour non-cross resistant anthraquinone analogues. Synthesis and molecular basis of the cytotoxic activity towards K562/DOX cells.

Authors:  J Tarasiuk; B Stefańska; I Plodzich; K Tkaczyk-Gobis; O Seksek; S Martelli; A Garnier-Suillerot; E Borowski
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

8.  Differential Coupling of Binding, ATP Hydrolysis, and Transport of Fluorescent Probes with P-Glycoprotein in Lipid Nanodiscs.

Authors:  Mavis Jiarong Li; Abhinav Nath; William M Atkins
Journal:  Biochemistry       Date:  2017-05-04       Impact factor: 3.162

9.  Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.

Authors:  Jaclyn N Harper; Stephen H Wright
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-03

10.  Structural mechanism of the simultaneous binding of two drugs to a multidrug-binding protein.

Authors:  Maria A Schumacher; Marshall C Miller; Richard G Brennan
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.